georgeclerk
- Pfizer (NYSE:PFE) and privately held Quotient Therapeutics will work together to analyze somatic mutations in diseased patient tissue to discover novel targets and potentially develop new treatments for cardiovascular and kidney diseases.
- Quotient’s Somatic Genomics platform will be used to identify potential links between genes and the diseases.
- Financial terms were not disclosed.
- The latest deal follows one between venture capital company Flagship Pioneering, which founded Quotient, and Pfizer that began in July 2023. That arrangement is to discover programs that address unmet medical needs.
